Phase I clinical and pharmacological studies of 20-(S)-camptothecin and 20-(S)-9-nitrocamptothecin as anticancer agents

Annals of the New York Academy of Sciences

Volumn 803, Issue , 1996, Pages 224-230

  Natelson, Ethan A ^a,b   Giovanella, Beppino C ^a   Verschraegen, Claire F ^a   Fehir, Kim M ^a   De Ipolyi, Peter D ^a   Harris, Nick ^a   Stehlin, John S ^a  

^a St Joseph's Medical Center Houston   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; RUBITECAN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HEMORRHAGIC CYSTITIS; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL;

EID: 0030453707     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1996.tb26392.x     Document Type: Conference Paper

References (14)

1. POTMESIL, M. 1944. Camptothecins: From bench research to hospital wards. Cancer Res. 54: 1431-1439.
2. PANTAZIS, P. 1995. The water-insoluble camptothecins: Promising anticancer drugs. Cancer J. 8: 119-123.
3. SLICHENMYER, W. J., E. K. ROWINSKY, R. C. DONEHOWER & S. H. KAUFMANN. 1993. The current status of camptothecin analogues as antitumor agents. J. Natl. Cancer Inst. 85: 271-291.
4. WALL, M. E., M. C. WANI, C. E. COOK, K. H. PALMER, A. T. MCPHAIL & G. A. SIM. 1966. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J. Am. Chem. Soc. 88: 388-3890.
5. GOVINDACHARI, T. R., & N. VISWANATHAN. 1972. Alkaloids of Mappia foetida. Phytochemistry 11: 3529-3531.
6. GOTTLIEB, J. A., & J. K. LUCE. 1972. Treatment of malignant melanoma with camptothecin (NSC-100880) Cancer Chemother. Rept. 56: 103-105.
7. HERTZBERG, R. P., M. J. CARANFA, K. G. HOLDERN, D. R. JAKAS, G. CALLAGER, M. R. MATTERN, S. MONG, J. O. BARTUS, R. K. JOHNSON & W. T. KINGSBURY. 1989. Modification of the hydroxy lactone ring of camptothecin: Inhibition of mammalian topoisomerase I and biological activity. J. Med. Chem. 32: 715-720.
8. SCHNEIDER, E., Y. H. HSIANG & L. LIU. 1990. DNA topoisomerases as anticancer drug targets. Adv. Pharmacol. 21: 149-183.
9. GIOVANELLA, B. C., H. R. HINZ, A. J. KOZIELSKI, J. S. STEHLIN, JR., R. SILBER & M. POTMESIL. 1991. Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(s)-camptothecin. Cancer Res. 51: 3052-3055.
10. STEHLIN, J. S., JR., E. A. NATELSON, H. R. HINZ, B. C. GIOVANELLA, P. D. DE IPOLYI, K. M. FEHIR, T. P. TREZONA, D. M. VARDEMAN, N. J. HARRIS, A. K. MARCEE, A. J. KOZIELSKI & A. RUIZ-RAZURA. 1995. Phase I clinical trial and pharmacokinetics results with oral administration of (20)-S-camptothecin. In Camptothecins, New Anticancer Agents, Chap. 5. M. Potmesil & H. Pinedo, Eds.:59-65 CRC Press. Boca Raton, FL.
11. RUBIN, E., V. WOOD, A. BHARTI, D. TRITES, C. LYNCH, S. HURWITZ, S. BARTEL, S. LEVY, A. ROSOWSKY, D. TOPPEMEYER & D. KUFE. 1995. A Phase I and pharmakokinetic study of a new camptothecin derivative, 9-aminocamptothecin. Clin. Cancer Res. 1: 269-276.
12. MI, Z. & T. G. BURKE. 1994. Marked interspecies variations concerning interactions of camptothecin with serum albumin. Biochemistry 33: 12540-12545.
13. HINZ, H. R., N. J. HARRIS, E. A. NATELSON & B. C. GIOVANELLA. 1994. Pharmacokinetics of the in vivo and in vitro conversion of 9-nitro-20-(S)-camptothecin to 9-amino-20-(S)-camptothecin in humans, dogs, and mice. Cancer Res. 52: 3096-3100.
14. PANTAZIS, P., N. J. HARRIS, J. MENDOZA & B. C. GIOVANELLA. 1994. Conversion of 9-nitro-camptothecin to 9-amino-camptothecin by human blood cells in vitro. Eur. J. Haematol. 53: 246-248.